Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down

Key Takeaways NVS Q2 EPS rose to $2.42 on 12% revenue growth, led by key drugs like Kisqali, Entresto, and Pluvicto. Novartis raised 2025 core income growth outlook to low teens amid strong product and pipeline performance. Cosentyx missed sales estimates and CFO Harry Kirsch's retirement announcement dampened investor sentiment.Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income.Core earnings (exclud ...